Gilead Sciences (GILD) Net Margin (2009 - 2026)
Gilead Sciences' (GILD) quarterly Net Margin came in at 29.04% in Q1 2026, up 931.0% YoY from 2.82% in Q1 2025, and down 8.97% on a QoQ basis from 31.9% in Q4 2025.
Gilead Sciences (GILD) Net Margin (2009 - 2026) Analysis & Trends
Gilead Sciences (GILD) has 18 years of Net Margin data on file, last reported at 29.04% in Q1 2026.
- Quarterly Net Margin rose 931.0% year-over-year to 29.04% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 32.16% (up 1140.0% YoY) and the FY2025 annual result came in at 28.9%, up 2724.0% from the prior year.
- Net Margin slipped to 29.04% in Q1 2026, from 31.9% in the prior quarter.
- In the past five years, Net Margin ranged from a high of 39.28% in Q3 2025 to a low of 62.38% in Q1 2024.
- A 5-year average of 17.43% and a median of 22.1% in 2022 frame the typical range for Net Margin.
- Annual changes were most pronounced in 2024 — Net Margin tumbled 7788 bps — and 2025, when it jumped 8211 bps.
- Tracing GILD's Net Margin over 5 years: stood at 22.1% in 2022, then slipped by 10 bps to 19.9% in 2023, then advanced by 18 bps to 23.54% in 2024, then surged by 35 bps to 31.9% in 2025, then retreated by 9 bps to 29.04% in 2026.
- The last three Net Margin figures came in at 29.04% (Q1 2026), 31.9% (Q4 2025), and 39.28% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.88 Bn | 625.12 Bn | 17.26 Bn | 21.86% |
| 2 | AbbVie | 463.46 Bn | 456.89 Bn | 12.70 Bn | 21.28% |
| 3 | Merck | 367.92 Bn | 360.78 Bn | 12.21 Bn | -8.05% |
| 4 | Novartis Ag | 297.71 Bn | 290.02 Bn | 11.24 Bn | 22.65% |
| 5 | Astrazeneca | 255.55 Bn | 250.65 Bn | 12.86 Bn | 16.30% |
| 6 | Amgen | 234.52 Bn | 220.53 Bn | 7.24 Bn | 23.62% |
| 7 | Gilead Sciences | 178.22 Bn | 175.04 Bn | 6.22 Bn | -134.51% |
| 8 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | -1.58% |
| 9 | Gsk | 105.32 Bn | 101.15 Bn | 8.24 Bn | 5.17% |
| 10 | Sanofi | 54.20 Bn | 46.82 Bn | 10.79 Bn | 2.96% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -134.51% |
| Mar 31, 2026 | 29.04% |
| Dec 31, 2025 | 31.90% |
| Sep 30, 2025 | 39.28% |
| Jun 30, 2025 | 27.69% |
| Mar 31, 2025 | 19.72% |
| Dec 31, 2024 | 23.54% |
| Sep 30, 2024 | 16.61% |
| Jun 30, 2024 | 23.22% |
| Mar 31, 2024 | -62.38% |
| Dec 31, 2023 | 19.90% |
| Sep 30, 2023 | 30.80% |
| Jun 30, 2023 | 15.74% |
| Mar 31, 2023 | 15.49% |
| Dec 31, 2022 | 22.10% |
| Sep 30, 2022 | 25.36% |
| Jun 30, 2022 | 18.13% |
| Mar 31, 2022 | 0.18% |
| Dec 31, 2021 | 5.19% |
| Sep 30, 2021 | 34.85% |